Skip to main content
. 2003 Nov 25;362(9397):1733–1745. doi: 10.1016/S0140-6736(03)14854-4

Table 2.

Efficacy of influenza vaccine in preventing laboratory-confirmed symptomatic influenza in populations of children, working adults, and community-dwelling elderly people

Population Vaccine and dose Study Outcome Efficacy (%; 95% CI)
Children Split product and surface antigen, 15 μg Random-effects meta-analysis1 of RCTs64, 65, 66, 67, 68 Symptomatic laboratory-confirmed influenza 80 (74–90)
Adults of working age Split product, 15 μg Random-effects meta-analysis1 of RCTs69, 70 Symptomatic laboratory-confirmed influenza; laboratory-confirmed influenza 77 (66–85)
Community-dwelling elderly Surface antigen, 15 μg RCT71 Laboratory-confirmed influenza 52 (29–67)
Elderly people in welfare nursing homes Split product, 15 μg Prospective cohort study72 Symptomatic laboratory-confirmed influenza 60 (NA)

NA=not available; RCT=randomised controlled trial.